Proximity to Ventura County is required, and weekend work may be needed for experiments.
PBS Biotech designs, manufactures, and sells single-use bioreactor systems and offers process development and technical support for cell therapy manufacturing. Its core Vertical-Wheel technology provides gentle, homogeneous mixing suitable for shear-sensitive cells like iPSCs and MSCs, enabling scalable suspension or microcarrier culture from research to clinical production. The company operates a B2B model, supplying equipment and disposable components along with customized process development services to academic, biotech, and pharmaceutical customers. With an ISO 9001:2015 certified facility and plans to scale to over $100 million in annual revenue, PBS Biotech aims to expand manufacturing capacity to support commercialization of cell therapies.
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$49M
Headquarters
Camarillo, California
Founded
2006
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
Single-use bioreactor manufacturer, PBS Biotech, recently closed a private $10M funding round with BroadOak Capital Partners. The financing will enable the c...
PBS Biotech wins 2026 cell Products Development of the Year award. Jul 21, 2026, 07:00 ET Recognition Highlights Company's Leadership in Advancing Linearly Scalable, Advanced Cell Therapy Manufacturing CAMARILLO, Calif., July 21, 2026 /PRNewswire/ - PBS Biotech, a leading developer of innovative single-use bioreactor technologies for cell therapy manufacturing, today announced it has been named Cell Therapy Products Development of the Year 2026 by Life Sciences Review. The company was also recognized among the publication's Top Companies in Cell and Gene Therapy, underscoring PBS Biotech's growing impact on the future of advanced therapeutic manufacturing. The recognition reflects PBS Biotech's continued commitment to helping cell therapy developers overcome one of the industry's greatest challenges: reliably scaling manufacturing while preserving cell quality and function. Through its patented Vertical-Wheel(R) bioreactor technology, PBS Biotech enables gentle, low-shear cell culture that supports the expansion and differentiation of a broad range of sensitive cell types, from early process development through commercial manufacturing. "As cell therapies continue to transform medicine, manufacturers need technologies that eliminate the traditional tradeoff between scalability and cell quality," said Martin Simonetti, Chief Executive Officer of PBS Biotech. "We're honored that Life Sciences Review has recognized our team's dedication to advancing manufacturing solutions that help bring life-changing therapies to patients faster." Unlike conventional stirred-tank bioreactors, PBS Biotech's Vertical-Wheel platform was specifically engineered to create homogeneous mixing with exceptionally low shear forces, providing an environment well suited for sensitive cell types including induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), T cells, NK cells, CAR-T, CAR-NK, and pancreatic islet cells. The technology offers linear scalability from research through manufacturing, enabling customers to simplify process development and accelerate technology transfer. In its feature, Life Sciences Review highlighted PBS Biotech's customer-centric approach, commitment to innovation, and expanding collaborations across the cell and gene therapy ecosystem. The publication also recognized the company's role in helping developers address critical manufacturing bottlenecks as more cell therapies advance toward commercialization. "This recognition belongs to our employees, customers, collaborators, and partners who continue pushing the boundaries of regenerative medicine," Simonetti added. "Together, we're building the manufacturing foundation that will enable the next generation of cell therapies to reach more patients around the world." As demand for scalable, robust manufacturing platforms continues to grow, PBS Biotech remains focused on expanding its technology portfolio, supporting customer success, and advancing manufacturing solutions that accelerate the commercialization of transformative cell therapies. About PBS Biotech PBS Biotech is a biotechnology company dedicated to advancing the manufacture of next-generation cell therapies through innovative bioreactor technologies. Its patented Vertical-Wheel(R) bioreactor platform delivers gentle, low-shear mixing with scalable performance to support process development, clinical manufacturing, and commercial production. PBS Biotech partners with leading biotechnology companies, CDMOs, and academic institutions worldwide to accelerate the development and commercialization of life-changing cell therapies. About Forward-Looking Statements This press release contains forward-looking statements regarding PBS Biotech's future plans, expectations, and business outlook, including statements related to the development, adoption, and commercialization of cell therapy manufacturing technologies. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. PBS Biotech undertakes no obligation to update any forward-looking statements as a result of new information, future events, or otherwise. Media Contact SOURCE PBS Biotech Inc.
PBS Biotech raises $17M in Growth funding.
PBS Biotech raised $17 million in growth capital from Avego Management and BroadOak Capital Partners to enhance product innovation, process development, and quality systems. The company is expanding its ISO 9001:2015 manufacturing capacity to support over $100 million in annual revenue by mid-2025. PBS appointed Terrell Mathews as Chief Commercial Officer and Erik Wiberg as Chief Financial Officer to drive strategic growth and strengthen its market position in the cell therapy industry.
/PRNewswire/ -- PBS Biotech ("PBS"), a provider of innovative single-use bioreactor systems and bioprocess development services, has secured $17 million in...